Latest results support GlaxoSmithKline's plan to file malaria vaccine RTS,S in 2014

• 
  

GlaxoSmithKline announced Tuesday that results from a Phase III trial support plans to file for approval with the European Medicines Agency for its malaria vaccine candidate RTS,S next year. Results indicated that over 18 months of follow-up, RTS,S was shown to almost halve the number of malaria cases in young children and to reduce by around a quarter the malaria cases in infants. CEO Andrew Witty remarked "while we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive."

**To read more Top Story articles, click here.